Afficher la notice abrégée

Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study

dc.rights.licenseopenen_US
dc.contributor.authorGUILLO, Lucas
dc.contributor.authorFLACHAIRE, Benoit
dc.contributor.authorAVOUAC, Jérôme
dc.contributor.authorDONG, Catherine
dc.contributor.authorNACHURY, Maria
dc.contributor.authorBOUGUEN, Guillaume
dc.contributor.authorBUISSON, Anthony
dc.contributor.authorCAILLO, Ludovic
dc.contributor.authorFUMERY, Mathurin
dc.contributor.authorGILLETTA, Cyrielle
dc.contributor.authorHÉBUTERNE, Xavier
dc.contributor.authorLAFFORGUE, Pierre
dc.contributor.authorLAHARIE, David
dc.contributor.authorMAHÉ, Emmanuel
dc.contributor.authorMAROTTE, Hubert
dc.contributor.authorNANCEY, Stéphane
dc.contributor.authorOTTAVIANI, Sébastien
dc.contributor.authorSALMON, Jean-Hugues
dc.contributor.authorSAVOYE, Guillaume
dc.contributor.authorSERRERO, Mélanie
dc.contributor.authorUZZAN, Mathieu
dc.contributor.authorVIGUIER, Manuelle
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorRICHEZ, Christophe
dc.contributor.authorPEYRIN-BIROULET, Laurent
dc.contributor.authorSEKSIK, Philipe
dc.contributor.authorPHAM, Thao
dc.contributor.authorAH-SOUNE, Philippe
dc.contributor.authorARAB, Nadia
dc.contributor.authorBEAUGERIE, Laurent
dc.contributor.authorBOLKO, Loïs
dc.contributor.authorBONNET, Joelle
dc.contributor.authorBOUHNIK, Yoram
dc.contributor.authorBOURRIER, Anne
dc.contributor.authorBRAZIER, Franck
dc.contributor.authorCARBONNEL, Franck
dc.contributor.authorCHARKAOUI, Maeva
dc.contributor.authorCHARLOT-LAMBRECHT, Isabelle
dc.contributor.authorCHUPIN, Antoine
dc.contributor.authorCOMBIER, Alice
dc.contributor.authorCOUDERC, Marion
dc.contributor.authorCOURY-LUCAS, Fabienne
dc.contributor.authorDESJEUX, Ariadne
dc.contributor.authorDUVEAU, Nicolas
dc.contributor.authorGRASLAND, Anne
dc.contributor.authorGRIMAUD, Jean-Charles
dc.contributor.authorGUENNOC, Xavier
dc.contributor.authorLANDMAN, Cécilia
dc.contributor.authorNION-LARMURIER, Isabelle
dc.contributor.authorLEBERRE, Catherien
dc.contributor.authorLEENHARDT, Romain
dc.contributor.authorGOFFIC, Aude Le
dc.contributor.authorMONTAUDIE, Henri
dc.contributor.authorMOREL, Jacques
dc.contributor.authorPASSERON, Thierry
dc.contributor.authorCOLLARD, Jeanne-Marie Perotin
dc.contributor.authorPOISNEL, Elodie
dc.contributor.authorPRADEL, Vincent
dc.contributor.authorSOUBRIER, Martin
dc.contributor.authorSOKOL, Harry
dc.contributor.authorTOUSSIROT, Eric
dc.contributor.authorTRANG, Caroline
dc.contributor.authorMINH, My-Linh Trans
dc.contributor.authorTRIJAU, Sophie
dc.contributor.authorVERHOEVEN, Frank
dc.contributor.authorVIENNOT, Stéphanie
dc.contributor.authorWENDLING, Daniel
dc.date.accessioned2024-09-17T10:07:36Z
dc.date.available2024-09-17T10:07:36Z
dc.date.issued2023-01
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201622
dc.description.abstractEnBackground: Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs. Methods: We conducted a French ambispective multicenter cohort study from September 2020 to May 2021, including adults’ patients with 1 or 2 IMIDs and treated at least 3-month with COMBIO. Results: Overall, 143 patients were included. The most common IMIDs were Crohn's disease (63.6%), axial spondyloarthritis (37.7%), and ulcerative colitis (14%). Half of patients had only one IMID, of which 60% were Crohn's disease. Mean duration of COMBIO was 274.5±59.3 weeks, and COMBIO persistence at 104 weeks was estimated at 64.1%. The most frequent COMBIOs combined anti-TNF agents with vedolizumab (30%) or ustekinumab (28.7%). Overall, 50% of patients achieved significant and 27% mild-to-moderate improvement in patient-reported outcomes. Extended duration of COMBIO (aOR=1.09; 95% CI: 1.03-1.14; p=0.002) and diagnoses of two IMIDs (aOR=3.46; 95%CI: 1.29-9.26; p=0.013) were associated with significant improvement in patient-reported outcomes. Incidence of serious infection during COMBIO was 4.51 per 100 person-years (95% CI 2.20-8.27) and 5 COMBIOs were discontinued due to adverse events. Conclusions: COMBIO can be effective and safe in patients with refractory/overlapping IMIDs.
dc.language.isoENen_US
dc.subject.enCombination therapy
dc.subject.enMolecular targeted therapy
dc.subject.enImmune-mediated inflammatory diseases
dc.title.enEfficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.dld.2022.07.012en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed35985961en_US
bordeaux.journalDigestive and Liver Diseaseen_US
bordeaux.page61-68en_US
bordeaux.volume55en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Digestive%20and%20Liver%20Disease&rft.date=2023-01&rft.volume=55&rft.issue=1&rft.spage=61-68&rft.epage=61-68&rft.au=GUILLO,%20Lucas&FLACHAIRE,%20Benoit&AVOUAC,%20J%C3%A9r%C3%B4me&DONG,%20Catherine&NACHURY,%20Maria&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
ImmunoConcept_DigLiverDis_2023 ...
Taille:
628.9Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée